Cross-cohort analysis identified an immune checkpoint-based signature to predict the clinical outcomes of neuroblastoma
Authors:
Open Access
- 2 May 2023
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 11 (5) , e005980
Abstract
Background Neuroblastoma (NB) places a substantial health burden on families worldwide. This study aimed to develop an immune checkpoint-based signature (ICS) based on the expression of immune checkpoints to better assess patient survival risk and potentially guide patient selection for immunotherapy of NB. Methods Immunohistochemistry integrated with digital pathology was used to determine the expression levels of 9 immune checkpoints in 212 tumor tissues used as the discovery set. The GSE85047 dataset (n=272) was used as a validation set in this study. In the discovery set, the ICS was constructed using a random forest algorithm and confirmed in the validation set to predict overall survival (OS) and event-free survival (EFS). Kaplan-Meier curves with a log-rank test were drawn to compare the survival differences. A receiver operating characteristic (ROC) curve was applied to calculate the area under the curve (AUC). Results Seven immune checkpoints, including PD-L1, B7-H3, IDO1, VISTA, T-cell immunoglobulin and mucin domain containing-3 (TIM-3), inducible costimulatory molecule (ICOS) and costimulatory molecule 40 (OX40), were identified as abnormally expressed in NB in the discovery set. OX40, B7-H3, ICOS and TIM-3 were eventually selected for the ICS model in the discovery set, and 89 patients with high risk had an inferior OS (HR 15.91, 95% CI 8.87 to 28.55, pConclusions We propose an ICS that significantly differentiates between low-risk and high-risk patients, which might add prognostic value to age and provide clues for immunotherapy in NB.Keywords
Funding Information
- Guangzhou Women and Children’s Medical Center (3001151-04)
This publication has 42 references indexed in Scilit:
- The clinical impact of ICOS signal in colorectal cancer patientsOncoImmunology, 2016
- Rationale for anti-OX40 cancer immunotherapyEuropean Journal of Cancer, 2016
- The Inducible Costimulator Augments Tc17 Cell Responses to Self and Tumor TissueThe Journal of Immunology, 2015
- Natural Killer Cells and Neuroblastoma: Tumor Recognition, Escape Mechanisms, and Possible Novel Immunotherapeutic ApproachesFrontiers in Immunology, 2014
- Association Between Postoperative Troponin Levels and 30-Day Mortality Among Patients Undergoing Noncardiac SurgeryJAMA, 2012
- Recent Advances in NeuroblastomaNew England Journal of Medicine, 2010
- Statistical Evaluation of a BiomarkerAnesthesiology, 2010
- Favorable Prognosis for Patients 12 to 18 Months of Age With Stage 4 Nonamplified MYCN Neuroblastoma: A Children's Cancer Group StudyJournal of Clinical Oncology, 2005
- Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)JNCI: Journal of the National Cancer Institute, 2005
- Association of Multiple Copies of the N-mycOncogene with Rapid Progression of NeuroblastomasNew England Journal of Medicine, 1985